These mutations are frequently associated with core-binding factor (CBF) AML, a subtype known for retaining differentiation capacity and exhibiting a relatively favorable clinical course, partly due to responsiveness to tyrosine kinase inhibitors [50,51]. Here, CEBPZ is linked to acute myeloid leukemia.